233 related articles for article (PubMed ID: 31857620)
1. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
[TBL] [Abstract][Full Text] [Related]
2. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
3. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
[TBL] [Abstract][Full Text] [Related]
4. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.
Soko ND; Chimusa E; Masimirembwa C; Dandara C
Pharmacogenomics J; 2019 Jun; 19(3):240-248. PubMed ID: 30100615
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
[TBL] [Abstract][Full Text] [Related]
7. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
8. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
[TBL] [Abstract][Full Text] [Related]
9. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
10. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Zalikowski J; Chen Y; Kim K; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):329-40. PubMed ID: 25630984
[TBL] [Abstract][Full Text] [Related]
13. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
14. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
16. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
17. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
18. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]